Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewUPF 648
说明： Potent kynurenine 3-monooxygenase (KMO) inhibitor
化学名： (1S,2S)-2-(3,4-Dichlorobenzoyl)cyclopropanecarboxylic acid
纯度： ≥98% (HPLC)
生物活性 for UPF 648
UPF 648 is a potent kynurenine 3-monooxygenase (kynurenine 3-hydroxylase; KMO) inhibitor (IC50 = 20 nM). Increases kynurenic acid levels, and decreases 3-HK and QUIN levels in cerebrum and liver of neonatal rodents. Neuroprotective in a Drosophila model of Huntington's disease.
技术数据 for UPF 648
| 分子量 | 259.09 |
| 公式 | C11H8Cl2O3 |
| 储存 | Store at +4°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 213400-34-1 |
| PubChem ID | 9859947 |
| InChI Key | ZBRKMOHDGFGXLN-BQBZGAKWSA-N |
| Smiles | [H][C@]1([C@@H]([C@](O)=O)C1)C(C2=CC=C(Cl)C(Cl)=C2)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for UPF 648
参考文献 for UPF 648
参考文献是支持产品生物活性的出版物。
Ceresoli-Borroni et al (2007) Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications. J.Neurosci.Res. 85 845 PMID: 17279543
Amaral et al (2013) Structural basis of kynurenine 3-monooxygenase inhibition. Nature 496 382 PMID: 23575632
Amori et al (2009) On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J.Neurochem. 109 316 PMID: 19226371
Campesan et al (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr.Biol. 21 961 PMID: 21636279
按产品操作查看相关产品
关键词: UPF 648, UPF 648 supplier, UPF648, potent, kynurenine, 3-monooxygenase, 3-hydroxylase, KMO, inhibitors, inhibits, huntington's, disease, KYNA, 3-hk, QUIN, neuroprotective, Hydroxylases, Kynurenine, 4926, Tocris Bioscience
1 篇 UPF 648 的引用文献
引用文献是使用了 Tocris 产品的出版物。 UPF 648 的部分引用包括：
NULL et al (2020) ACNP 59th annual meeting: panels, mini-panels and study groups. Neuropsychopharmacology 45 24473 PMID: 33279933
UPF 648 的评论
目前没有该产品的评论。 Be the first to review UPF 648 and earn rewards!
Have you used UPF 648?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Multiple Sclerosis Poster
Multiple sclerosis (MS) is an autoimmune disease that is characterized by focal demyelination and axon degeneration in the central nervous system. This poster summarizes the neurobiology and current therapies of MS.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.